Companies › Medigen Biotechnology
1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Allogeneic Magicell-NK Allogeneic natural killer cells for immunotherapy | – | Phase 1 | Colon Cancer Stage I; Pancreatic Carcinoma Stage II | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05394714 | Allogeneic Magicell-NK | Phase 1 | Colon Cancer Stage I | Oncology | Jun 2028 |
| NCT06730009 | Allogeneic Magicell-NK | Phase 1 | Pancreatic Carcinoma Stage II | Oncology | Jan 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.